Effect of dupilumab treatment in a severe asthma patient with EGPA

Type 2 cytokines (IL-4, IL-5, and IL-13) have a key role in inflammatory processes in asthma and eosinophilic granulomatosis with polyangiitis, and biologic therapies are new therapeutic opportunities for patients with asthma and eosinophilic granulomatosis with polyangiitis. Airway remodeling may condition overall therapeutic response in severe asthmatic patients. Alterations of the airway wall may change over time, at least partly because of the effect of treatment. Anti-IL-4/IL-13 strategy is able to resolve goblet cell hyperplasia seen in severe asthmatic patients.